![Hai Ge Shen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hai Ge Shen
Corporate Officer/Principal at Genfleet Therapeutics (Shanghai), Inc.
Hai Ge Shen active positions
Companies | Position | Start | End |
---|---|---|---|
Genfleet Therapeutics (Shanghai), Inc.
![]() Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | Corporate Officer/Principal | - | - |
Director/Board Member | - | - |
Career history of Hai Ge Shen
Statistics
International
China | 2 |
Operational
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Genfleet Therapeutics (Shanghai), Inc.
![]() Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | Commercial Services |
- Stock Market
- Insiders
- Hai Ge Shen
- Experience